

[Thermo Fisher introduces hematology-oncology portfolio](#)

written by CAP TODAY
November 19, 2020

November 2020—Thermo Fisher Scientific announced the availability of its OncoPrint Myeloid Assay GX, the first in a series of clinical research assays available from the company's new portfolio of hematology-oncology assays for the Ion Torrent Genexus System.

The panel enables simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in one day. It also provides researchers the ability to profile 40 DNA targets and 29 fusion driver genes, enabling the detection of more than 600 fusion isotypes, the company reports, to identify biomarkers associated with myeloproliferative neoplasm, acute myeloid leukemia, and myelodysplastic syndrome.

Thermo Fisher plans to introduce additional hematology-oncology clinical research assays for B-cell and T-cell clonality and somatic hypermutation assessment through immune repertoire sequencing to study lymphoid malignancies, including chronic lymphocytic leukemia, acute lymphoblastic leukemia, multiple myeloma, and Hodgkin and non-Hodgkin lymphomas. The company will also introduce a lymphoid gene panel.

[Thermo Fisher Scientific](#), 866-356-0354



©2026 CAP TODAY, all rights reserved.